Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond ...

Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond well to conventional medical treatments, often leading to significant ...

Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond ...

Microvascular decompression of the trigeminal nerve root entry zone is superior among neurosurgical procedures in the long-term relief of TN owing to neurovascular compression, yet carries ...

Sufferers say the pain caused by the nerve disorder is so debilitating that they can’t smile, laugh or even make eye contact with another person.

The anticonvulsant fosphenytoin is safe and effective in quickly decreasing pain from sudden attacks of acute trigeminal ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) filed its 510(k) submission to the FDA for trigeminal nerve ablation ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

Technologies has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.

Trigeminal neuralgia is typically treated with medication or invasive procedures, including microvascular decompression, radiosurgery, or other percutaneous techniques. The OneRF trigeminal nerve ...

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from ...